follicular function by use of colour doppler imaging to measure blood¯ow in the wall of the leading ovarian follicle. Changes in frequency caused when an ultrasound beam interacts with moving red cells can be measured and 309
social and evolutionary effects of ®re, as well as the malign consequences of its misuse. In one of the many humorous asides that leaven the book he quotes Bob Newhart's immortal monologue about Walt Raleigh's effort to sell his noxious weed to an of®cial from the British West India Company. The front cover of the book suggests that Greaves the evolutionary biologist gives quite a lot of weight to culture and environment, with his illustration of a pair of native North Americans enjoying their Romeo y Giulliettas. Looking ahead, Greaves tempers his enthusiasm for the reductionists' magic bullets with pragmatic information on simpler remedies, from non-steroidal anti-in¯ammatory drugs upwards in the evolutionary scale of drugs. He describes himself and others of his ilk as inveterate optimists. (I too am an optimist; though, nearer the clinical coalface, my adjective is`incurable'). Most oncologists now practising have been trained at the dawn of systemic anticancer therapy, which began in earnest in the USA in the 1970s and later, against much professional scepticism, in the UK. Even with the poor knowledge base and the crude technology, we have come a long way in my 25 years of practice. Clinical oncologists of every hue would be delighted to consign to the dustbin of history treatments that are expensive, frightening and toxic. If Greaves and others like him are right, we are on the verge of a new era in which dysfunctional proteins will be targeted precisely and missing pieces will be placed in the incomplete cellular jigsaw that characterizes many of these diseases. As I worked through this magni®cent book, so my enthusiasm for the message and its philosophy grew. It is intended for non-scientists; but I can think of few clinicians or scientists, specialized as we all are nowadays, who would not learn something useful from it. This edition of the British Medical Bulletin covers infertility, contraception, sexual dysfunction and the menopause. The editors are from Edinburgh and they have ensured good Scottish representation in the 20 chapters written by 35 authors. Some of the chapters will perhaps be mainly of interest to gynaecologists and scientists specializing in infertility. But the excellent results of intracytoplasmic sperm injection for the treatment of male infertility (better than in-vitro fertilization, IVF) reported by Campbell and Irvine cannot fail to impress any of us who come into contact with infertility patients.
R C F Leonard
Of wide interest too is the section in Richard Sharpe's chapter on occupation and lifestyle factors impacting on male fertility, together with seasonal¯uctuations in semen quality and quantity. Heat adversely affects the sperm counts of bakers, welders and glass-blowers as well as those who sit for long periods, such as taxi and lorry drivers, computer operators and people in wheelchairs. Exposure to constituents of plastics such as phthalates and to anabolic steroids can also reduce male fertility. Sperm counts tend to decline in the summer and are lower in men who live in urban areas.
So much is still unknown about reproduction. More than half of cases of premature ovarian failure are of unknown aetiology. Nevertheless, the new genetics is being applied to male infertility and both inherited conditions and mutations have now been clearly linked to male fertility problems. And there are ethical issues relating to intracytoplasmic sperm injection treatment, which can itself increase the chance of genetic defects. The genetics here is too technical for the general reader. There are too many abbreviations too, not all of which are spelled out when ®rst mentioned. I spent a long time looking for what CBAVD stood for and eventually found itÐcongenital bilateral absence of the vas deferens.
A recurring theme in this Bulletin is the development of blood vessels and the blood¯ow through them. The technical achievements are truly amazing. In Professor Stuart Campbell's department pioneering work on ultrasound scanning has produced images enhanced by`surface rendering' to give 3D pictures. Impressive images of the early embryo and of ovarian cysts can be obtained and tubal patency can be demonstrated by views of the¯ow along the fallopian tube by 3D colour power angiography. Ovarian stromal blood¯ow velocity is raised in polycystic ovarian syndrome. Also his team have developed monitoring of displayed. There is a signi®cant rise in peak systolic velocity from the time of the luteinizing hormone surge, indicating a marked increase in blood¯ow during the periovulatory phase. Good blood¯ow in the follicle is associated with better IVF outcomes. Good subendometrial blood¯ow has been found to correlate with uterine receptivity to implantation. Women with poor uterine perfusion have been treated with agents such as the ubiquitous sildena®l to try to increase blood¯ow and so to improve IVF success rates. However, no differences in blood¯ow have been detected so far in those with threatened miscarriage.
A whole chapter is devoted to angiogenesis in relation to the menstrual cycle. Angiogenesis is the development of new blood vessels by endothelial cell proliferation and outgrowth from pre-existing vessels. In the ovaries, uterus and placenta the vascular endothelium is active; in contrast, the endothelium is quiescent in adults, except during wound healing and tumour growth. For instance, blood ow in the corpus luteum in the mid-luteal phase is almost the greatest of any tissue in the body. This is a promising target for manipulation of reproductive function, including contraception, and is a spin-off from research being conducted in cancer. Anti-angiogenic agents (e.g. antagonists of vascular endothelial growth factor) could inhibit follicular growth and ovulation. Targeting the luteal phase would be the most likely option, prolonged suppression of angiogenesis would risk disruptive side-effects. Other conditions that could possibly be treated this way are ®broids and endometriosis.
This British Medical Bulletin is a good source of authoritative reviews on topics in human reproduction. It will be of particular interest to specialists but general practitioners will appreciate the chapters on the combined oral contraceptive pill, emergency contraception, erectile dysfunction and hormone replacement therapy. An increasing ability to identify tumour antigens, coupled with advances in immunization, has generated new enthusiasm for cancer vaccination strategies. Cancer Vaccines and Immunotherapy describes the underlying mechanisms and the therapeutic potential of this approach.
The short and lucid introduction is essential for an understanding of what follows: it deals with immunosurveillance and how it may be affected in cancer, with immune-mediated elimination of allogeneic tumours in animal models, with the successful treatment of Epstein± Barr virus related lymphoma in renal transplant patients by infusion of immune T cells, and with the way the immune system recognizes and processes tumour antigens, what induces self-tolerance, and which additional molecules are required for an effective immune response. A chapter on pox viruses, one of the principal delivery vehicles for tumour vaccines, serves as useful background to the discussion of clinical trials.
The hope, of course, is that vaccination will improve on the results of conventional therapies, especially for common tumours such as breast cancer. In this respect there has been much interest in the MUC1 gene, which encodes for an epithelial mucin overexpressed in malignant breast cells and associated with an altered pattern of glycosylation (though the relevance of this to cell behaviour is unknown). MUC1 can also act as a ligand for the adhesion molecule ICAM-1 and enhances antigen presentation to T cells, possibly via interaction with a lectin molecule. A multitude of antibodies have been raised to MUC1 and some are being used in clinical trials of immunotherapy for breast and ovarian cancer. Early results are promising and phase III studies are underway.
One of the key chapters deals with an approach termed SEREX (serological analysis of tumour antigens by recombinant cDNA expression cloning). This involves the construction of cDNA expression libraries from fresh tumour specimens and the selection of clones that elicit high-titre IgG antibody responses. Some of the advantages of this technique are that tumour lines do not have to be established, identi®ed genes are expressed in vivo and multiple antigens can be identi®ed with one screening course and sequenced immediately. By 1998 there were over nine hundred entries on the SEREX database. This technique may allow mapping of the antigenic pro®le of individual tumours, identi®cation of the antigens that elicit an immune response in cancer patients, and the development of polyvalent vaccines.
Although techniques of this kind offer hope that novel treatments will soon emerge, the overview in Cancer Vaccines and Immunotherapy sounds some notes of caution. Of the antigens identi®ed by SEREX few have reached the stage of preclinical trial, so the full limitations of the method have probably yet to emerge. Of the various delivery mechanisms for vaccines, all have advantages and disadvantages. And the remaining challenge is to optimize the design of clinical trials to ensure that vaccines are not only immunogenic and effective but also safe. This requires development of better tools for assessing immunological and clinical aspects. The choice of malignant target and stage of disease is also important.
Despite all the scienti®c advances there is still no certainty that cancer vaccines will work ef®ciently. The
